Home » Stocks » NEO

NeoGenomics, Inc. (NEO)

Stock Price: $55.29 USD -0.90 (-1.60%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Pre-market: $55.00 -0.29 (-0.53%) Jan 22, 8:08 AM
Market Cap 6.36B
Revenue (ttm) 425.32M
Net Income (ttm) -4.95M
Shares Out 110.46M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE 169.49
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $55.29
Previous Close $56.19
Change ($) -0.90
Change (%) -1.60%
Day's Open 56.71
Day's Range 54.75 - 57.00
Day's Volume 1,068,218
52-Week Range 20.50 - 57.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Accesswire - 2 weeks ago

FORT MYERS, FL / ACCESSWIRE / January 6, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract rese...

Accesswire - 2 weeks ago

FORT MYERS, FL / ACCESSWIRE / January 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract rese...

Accesswire - 2 weeks ago

FT. MYERS, FL / ACCESSWIRE / January 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, tod...

CNBC - 4 weeks ago

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Costco and Twitter

Other stocks mentioned: COST, MKSI, TWTR, ZNGA
Seeking Alpha - 4 weeks ago

NeoGenomics remains insulated and differentiated from peers via a plethora of offerings in clinical diagnostics, as a potential market-leader in oncology services. The growth vision looks at c...

Seeking Alpha - 2 months ago

NeoGenomics, Inc.'s (NEO) CEO Doug VanOort on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

NeoGenomics (NEO) delivered earnings and revenue surprises of 500.00% and -2.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 3 months ago

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 3 months ago

NeoGenomics (NEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Investment Research - 4 months ago

ANIK vs. NEO: Which Stock Is the Better Value Option?

Other stocks mentioned: ANIK
The Motley Fool - 5 months ago

The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.

Seeking Alpha - 5 months ago

NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q2 2020 Results - Earnings Call Transcript

Benzinga - 5 months ago

Shares of NeoGenomics (NASDAQ:NEO) rose 1% after the company reported Q2 results.

Zacks Investment Research - 5 months ago

NeoGenomics (NEO) delivered earnings and revenue surprises of 55.56% and 1.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 6 months ago

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 6 months ago

These pioneers will be winners however the pandemic plays out.

Other stocks mentioned: BNTX, ILMN
Investors Business Daily - 6 months ago

NeoGenomics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81. The post NeoGenomics Shows Market Leadership With Jump To 81 RS Rating appeare...

Investors Business Daily - 7 months ago

A Relative Strength Rating upgrade for NeoGenomics shows improving technical performance. Will it continue?

The Motley Fool - 8 months ago

Near-term headwinds won’t damage the long-term prospects of these two companies.

Other stocks mentioned: FB
The Motley Fool - 8 months ago

The company decided to pull the trigger on a combined offering of stock and debt to pad its balance sheet during uncertain times.

The Motley Fool - 8 months ago

Despite experiencing a double-digit decline in test volumes, the cancer genetics lab hasn't furloughed employees. It has even retooled labs to process COVID-19 swab and blood tests.

Seeking Alpha - 8 months ago

Neogenomics Inc. (NEO) CEO Doug VanOort on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

NeoGenomics (NEO) delivered earnings and revenue surprises of -200.00% and -0.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 8 months ago

Test volumes fell by double digits at the end of March compared with the year-ago period. How long does management think that trend will continue?

The Motley Fool - 10 months ago

Investors should prepare for the genetic testing industry to see a tangible slowdown in volumes due to the coronavirus pandemic.

Other stocks mentioned: EXAS, NVTA
The Motley Fool - 10 months ago

Growth stocks have been getting punished in the current market downturn, but investors with a long-term mindset will find plenty to like in the latest earnings report.

The Motley Fool - 10 months ago

Advances in precision medicine continue to propel the leader in oncology testing services.

The Motley Fool - 10 months ago

The cancer genetics company reported full-year 2019 operating results, but that's probably not the reason for the decline.

Seeking Alpha - 10 months ago

NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

NeoGenomics (NEO) delivered earnings and revenue surprises of 42.86% and 2.31%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 11 months ago

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 11 months ago

These two stocks are supported by solid long-term opportunities, but they couldn't be more different.

Other stocks mentioned: AWK
The Motley Fool - 1 year ago

Which biotech was a 37-bagger?

Other stocks mentioned: ABMD, ACAD, AXDX, DXCM, EXAS, JAZZ, NBIX, RGEN, SLP
The Motley Fool - 1 year ago

These genetic testing stocks took divergent paths in the final months of 2019, but they're solid options for investors with a long-term mindset.

Other stocks mentioned: NVTA
The Motley Fool - 1 year ago

Helping people stricken with illness can be richly rewarding in more ways than one.

Other stocks mentioned: ARQL, ARWR, EIDX, GH, KOD, MEDP, NVRO, THC, ZTS
The Motley Fool - 1 year ago

The cancer-focused genetic testing service provider upgraded its offerings to provide higher-quality data from the same biological samples. That should keep growth humming along.

Seeking Alpha - 1 year ago

NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q3 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

An excellent third-quarter performance for the genetic testing company has investors cheering.

Zacks Investment Research - 1 year ago

NeoGenomics (NEO) delivered earnings and revenue surprises of 16.67% and 5.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 1 year ago

These stocks have track records of success and plenty of growth ahead.

Other stocks mentioned: MRK, SGEN
The Motley Fool - 1 year ago

Most stocks in the industry cooled off from all-time highs. Will they keep sliding?

Other stocks mentioned: GHDX, NVTA
InvestorPlace - 1 year ago

These healthcare stocks are all worth a "buy" now. The healthcare sector will keep chugging along despite market volatility.

Other stocks mentioned: CATS, ENSG, FLGT, JYNT, VIEMF, VNRX
The Motley Fool - 1 year ago

It was a great month to be a genetic testing company.

Other stocks mentioned: EXAS, GHDX, NVTA
Investors Business Daily - 1 year ago

Investor's Business Daily: NeoGenomics, Inc.

Trump tariffs slam stocks: NeoGenomics breaks out.

Seeking Alpha - 1 year ago

NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and 5.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

The genetic testing leader continues to set new quarterly revenue records.

Zacks Investment Research - 1 year ago

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Seeking Alpha - 1 year ago

NeoGenomics' (NEO) CEO Doug VanOort on Q1 2019 Results - Earnings Call Transcript

About NEO

NeoGenomics operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationshi... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 2, 1999
CEO
Douglas M. VanOort
Employees
1,700
Stock Exchange
NASDAQ
Ticker Symbol
NEO
Full Company Profile

Financial Performance

In 2019, NeoGenomics's revenue was $408.83 million, an increase of 47.73% compared to the previous year's $276.74 million. Earnings were $8.01 million, an increase of 203.26%.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for NeoGenomics stock is "Strong Buy." The 12-month stock price forecast is 52.50, which is a decrease of -5.05% from the latest price.

Price Target
$52.50
(-5.05% downside)
Analyst Consensus: Strong Buy